Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti–Tumor Necrosis Factor-α Agents
- 1 July 2013
- journal article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 11 (7), 826-831
- https://doi.org/10.1016/j.cgh.2013.01.012
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic ReviewAmerican Journal of Gastroenterology, 2011
- Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose “Escalation” in Patients Losing ResponseJournal of Clinical Gastroenterology, 2011
- Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2010
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Optimizing the Use of Tumour Necrosis Factor Inhibitors in Crohnʼs DiseaseDrugs, 2010
- Long-Term Durability of Crohn’s Disease Treatment with InfliximabDigestive Diseases and Sciences, 2007
- Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trialGut, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseNew England Journal of Medicine, 2004
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002